+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Peptic Ulcer Drugs - Global Market Trajectory & Analytics

  • ID: 5309796
  • Report
  • April 2021
  • Region: Global
  • 136 pages
  • Global Industry Analysts, Inc
Global Peptic Ulcer Drugs Market to Reach $5.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Peptic Ulcer Drugs estimated at US$4.9 Billion in the year 2020, is projected to reach a revised size of US$5.9 Billion by 2027, growing at a CAGR of 2.6% over the analysis period 2020-2027. Proton Pump Inhibitors (PPIs), one of the segments analyzed in the report, is projected to record a 2.5% CAGR and reach US$4.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gastric Mucosal Protective Drugs segment is readjusted to a revised 3.3% CAGR for the next 7-year period.



The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 2.5% CAGR

The Peptic Ulcer Drugs market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1 Billion by the year 2027 trailing a CAGR of 2.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 2.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

H2 Receptor Antagonists Segment to Record 2.8% CAGR

In the global H2 Receptor Antagonists segment, USA, Canada, Japan, China and Europe will drive the 2.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$374.3 Million in the year 2020 will reach a projected size of US$458 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$652.8 Million by the year 2027.

Select Competitors (Total 46 Featured):
  • Abbott Laboratories
  • AstraZeneca PLC
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Daewoong Pharmaceutical Co., Ltd.
  • Eisai Co., Ltd.
  • Pharmaking Co., Ltd.
  • Taiho Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Co., Ltd.
  • Yuhan Corporation
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Peptic Ulcer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Peptic Ulcer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Peptic Ulcer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Proton Pump Inhibitors (PPIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Proton Pump Inhibitors (PPIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Proton Pump Inhibitors (PPIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Gastric Mucosal Protective Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Gastric Mucosal Protective Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Gastric Mucosal Protective Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for H2 Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for H2 Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for H2 Receptor Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 16: USA Current & Future Analysis for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 17: USA Historic Review for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: USA 15-Year Perspective for Peptic Ulcer Drugs by Segment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments for the Years 2012, 2020 & 2027
  • CANADA
  • Table 19: Canada Current & Future Analysis for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 20: Canada Historic Review for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: Canada 15-Year Perspective for Peptic Ulcer Drugs by Segment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 22: Japan Current & Future Analysis for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 23: Japan Historic Review for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 24: Japan 15-Year Perspective for Peptic Ulcer Drugs by Segment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments for the Years 2012, 2020 & 2027
  • CHINA
  • Table 25: China Current & Future Analysis for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: China Historic Review for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 27: China 15-Year Perspective for Peptic Ulcer Drugs by Segment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 28: Europe Current & Future Analysis for Peptic Ulcer Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 29: Europe Historic Review for Peptic Ulcer Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 30: Europe 15-Year Perspective for Peptic Ulcer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 31: Europe Current & Future Analysis for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: Europe Historic Review for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 33: Europe 15-Year Perspective for Peptic Ulcer Drugs by Segment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 34: France Current & Future Analysis for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 35: France Historic Review for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 36: France 15-Year Perspective for Peptic Ulcer Drugs by Segment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 37: Germany Current & Future Analysis for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: Germany Historic Review for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 39: Germany 15-Year Perspective for Peptic Ulcer Drugs by Segment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments for the Years 2012, 2020 & 2027
  • ITALY
  • Table 40: Italy Current & Future Analysis for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 41: Italy Historic Review for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 42: Italy 15-Year Perspective for Peptic Ulcer Drugs by Segment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 43: UK Current & Future Analysis for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: UK Historic Review for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 45: UK 15-Year Perspective for Peptic Ulcer Drugs by Segment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 46: Rest of Europe Current & Future Analysis for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 47: Rest of Europe Historic Review for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 48: Rest of Europe 15-Year Perspective for Peptic Ulcer Drugs by Segment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 49: Asia-Pacific Current & Future Analysis for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: Asia-Pacific Historic Review for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 51: Asia-Pacific 15-Year Perspective for Peptic Ulcer Drugs by Segment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments for the Years 2012, 2020 & 2027
  • REST OF WORLD
  • Table 52: Rest of World Current & Future Analysis for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 53: Rest of World Historic Review for Peptic Ulcer Drugs by Segment - Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 54: Rest of World 15-Year Perspective for Peptic Ulcer Drugs by Segment - Percentage Breakdown of Value Sales for Proton Pump Inhibitors (PPIs), Gastric Mucosal Protective Drugs, H2 Receptor Antagonists and Other Segments for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 46
Note: Product cover images may vary from those shown
Adroll
adroll